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Antimicrobial resistance (AMR) in Neisseria gonorrhoeae is a major public health concern
globally, compromising the treatment of gonorrhea and its severe sequelae [1–3]. In response
to emerging resistance to extended-spectrum cephalosporins (ESCs; cefixime and ceftriaxone),
many countries introduced dual antimicrobial therapy for gonorrhea (mainly ceftriaxone plus
azithromycin). Subsequently, resistance to the previous first-line treatment, cefixime, has
decreased in many countries, including England [4,5]. However, several imperatives remain:
increased surveillance of AMR (ideally including treatment outcomes and prescribing), rapid
point-of-care tests that can simultaneously detect gonococci and predict resistance to multiple
antimicrobials, novel antimicrobials with new mechanisms of action, and, ideally, an effective
gonococcal vaccine [1–5]. Furthermore, improved understanding of the emergence, evolution,
spread, and fitness of AMR in gonococci, which could predict future AMR scenarios and ide-
ally mitigate them and inform public health practices, is also crucial but has received less
attention.
In a research study in the latest issue of PLOS Medicine, Xavier Didelot and colleagues [6]
aimed to estimate the fitness cost and benefit of cefixime resistance in gonococci in men who
have sex with men (MSM) in England, using mathematical modeling and Bayesian inference.
They developed a stochastic compartmental model representing the natural history and trans-
mission of cefixime-sensitive and cefixime-resistant gonococcal strains. The authors assumed
that the resistant strain has a fitness cost that results in faster clearance from asymptomatic
infection. The model was then fitted to data on the total number of diagnoses and incidence of
cefixime-resistant gonorrhea from 2008 to 2014. Briefly, the investigators estimated that cefix-
ime treatment of cefixime-resistant strains was unsuccessful in 83% (95% credible interval
[CrI] 53%–99%) of cases, resulting in a potential fitness benefit of resistance. This benefit was
counterbalanced by the fitness cost when 31% (95% CrI 26%–36%) of patients were treated
with cefixime, and when >55% (95% CrI 44%–66%) of patients were treated with cefixime, the
resistant strain had a net fitness advantage over the susceptible strain. The study concludes
that a previously abandoned antimicrobial such as cefixime could be reintroduced for treat-
ment of a minority of gonorrhea patients without raising resistance levels.
Alternative hypotheses
Didelot and colleagues’ study [6] had important aims and represents a valuable addition to the
sparse literature on gonorrhea modeling specifically related to AMR. A major limitation of the
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study, however, is that the authors have not used their model to test alternative hypotheses that
could explain the decline in cefixime resistance levels. In particular, introduction of dual therapy
with ceftriaxone plus azithromycin, along with routine test-of-cure, in England in 2011 [7]
might have effectively started to replace the N. gonorrhoeae multiantigen sequence typing
(NG-MAST) G1407 lineage that accounted for most cefixime resistance and most of the verified
cefixime treatment failures in England and many other countries [8–11]. G1407 was especially
prevalent among MSM [8–10], and pharyngeal gonorrhea, which is effectively eradicated by
dual therapy, might have previously acted as a reservoir. This hypothesis is consistent with the
significant decrease in G1407 prevalence from 2009–2010 to 2013, associated with a significant
decline in cefixime resistance among MSM, in England and in Europe in general [10]. In addi-
tion, this decline in G1407 prevalence resulted in an increased susceptibility to ceftriaxone [5,8–
10], which is affected by the same ESC resistance mechanisms. The G1407 lineage appears to
also have a relatively high fitness because the first G1407 isolate with ESC resistance determi-
nants was identified in Japan in 2003 [12], and it has subsequently spread globally, accounting
for most ESC resistance and treatment failures [8–11]. Additionally, a significant fitness cost
resulting in rapidly decreasing cefixime resistance levels when cefixime is excluded from the
recommended treatment is not in accordance with data from several other countries. Japan
excluded cefixime and all other oral ESCs from the recommended treatment guideline in 2006,
and resistance to cefixime has remained at a high level [13,14]. Therefore, in addition to a possi-
ble fitness cost, the decrease in cefixime resistance has most likely been highly affected by clonal
replacements of G1407—and other gonococcal lineages associated with cefixime resistance—by
cefixime-susceptible lineages, which has been driven by the discontinuation of cefixime and use
of effective dual therapy (particularly the ceftriaxone component of the dual therapy).
Limitations of the current evidence base
The state-of-the-art framework that Didelot and colleagues [6] used to infer the transmission
dynamics of gonorrhea nicely illustrates the importance and power of such modeling studies.
However, the study also shows the weak evidence base for several key assumptions and model
parameters, resulting in large credible intervals that describe the transmission of sensitive and
resistant strains and other complex epidemiological processes. First, the authors assume that
the fitness cost solely acts through a reduction in the duration of asymptomatic infections, but
it could also be associated with lower transmissibility or a higher proportion of symptomatic
infections. Investigating the effects of these alternative fitness costs on the selection and spread
of gonococcal resistance is considerably more complex [15]. It is also important to note that
gonococcal AMR mechanisms do not necessarily cause significantly lower fitness, which
results in the persistence of AMR and multidrug-resistant strains even in the absence of obvi-
ous antimicrobial pressure through recommended gonorrhea treatment guidelines. The rea-
sons for this likely include that gonococci are effective in developing compensatory mutations
that restore the possible fitness cost of AMR determinants. Some AMR determinants (e.g.,
mtrR and gyrAmutations) appear to be able to even enhance the fitness of at least some gono-
coccal strains. Thus, many years after penicillin, tetracycline, and fluoroquinolones were no
longer recommended as treatments for gonorrhea, resistant strains continue to represent a sig-
nificant percentage of isolates globally [16].
Second, the study considers a homogenous population of MSM and does not take into
account heterogeneities in sexual behavior or practices, as others have done [15,17]. For some
antimicrobials with frequently induced resistance, such as ciprofloxacin, the rate at which
resistant gonorrhea spreads might be more affected by the treatment rate rather than by differ-
ent levels of sexual activity, but only in the absence of a fitness cost [15]. Furthermore, the
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calculation of the basic reproduction number (R0) for sensitive and resistant strains heavily
depends on assumptions about the level of heterogeneity in sexual behavior and sexual mixing
[18]. Therefore, Didelot and colleagues’ findings about the appropriate levels of treatment with
cefixime [6], which are based on results derived from R0, need to be treated with caution.
Third, we are lacking sufficient knowledge regarding the natural course, relative prevalence,
transmissibility, probability of developing symptoms, duration of symptoms, average time to
detection/treatment, effects of cotreatment, and pathogenicity of gonorrhea by anatomical
site. Consequently, these complexities cannot be appropriately considered in mathematical
models to date. Instead, the rate of transmission and the likelihood of developing symptoms
used in models are frequently an assumption of the average for any infection site, which is not
an ideal situation when these parameters differ significantly depending on the site of infection
and sexual practice.
Fourth, improved data about the frequency of gonorrhea treatment failures and type of
antimicrobial prescriptions (treatment and cotreatment) internationally are essential. For
instance, when cefixime monotherapy was recommended from 2005 to 2010 in England (and
Europe), azithromycin 1 g was also frequently administered empirically to eradicate concomi-
tant Chlamydia trachomatis infection [19], and azithromycin 1 g by itself cures most gonorrhea
cases [20]. Thus, dual therapy was also frequently administered before the introduction of the
dual therapy for gonorrhea, particularly to the high-risk group of MSM and especially when
pharyngeal gonorrhea was not excluded. Additionally, MSM are in general more frequently
screened/tested (because of high risk or partner notification) and subsequently treated, and
also, test of cure for these patients is not uncommon. Many gonorrhea cases among MSM
would consequently have been detected and appropriately treated (with dual therapy or only
ceftriaxone before or after test of cure) despite being asymptomatic, but Didelot and colleagues
[6] made the assumption that asymptomatic infections were not treated and only resolved
spontaneously or because of antimicrobials taken for other indications. As a result, the high
level (83%) of treatment failures for cefixime-resistant gonorrhea predicted by the model,
which also used the United Kingdom Gonococcal Resistance to Antimicrobials Surveillance
Programme (GRASP) cefixime resistance breakpoint [4] and not the higher clinical cefixime
resistance breakpoint stated by the European Committee on Antimicrobial Susceptibility Test-
ing (EUCAST; www.eucast.org), is overestimated.
Finally, we need an enhanced microbiological understanding regarding the genetic predis-
position of strains to develop resistance and the risk factors that are associated with emergence
and evolution of AMR (patient, gonococcal strains, and coinfecting/commensal bacteria) to be
able to take into account both direct transmission and de novo emergence of AMR and how
the proportion of these mechanisms differ depending on the population and antimicrobial
investigated. Many of these factors were not included in Didelot and colleagues’ model [6],
mostly because of the lack of appropriate evidence.
It also needs to be noted that the authors legitimately emphasize that some of the aspects
regarding limitations of the current evidence base mentioned above would likely influence the
dynamics of cefixime-sensitive and cefixime-resistant strains in a similar manner and would
not significantly affect the study’s main findings.
There are still few gonorrhea mathematical modeling studies specifically related to AMR, so
additional studies are encouraged, particularly using multidisciplinary approaches that take
into account microbiological, genomic, evolutionary, clinical, immunological, and epidemio-
logic data. Future modeling studies will be of value to inform AMR emergence and spread,
management of gonorrhea, and public health practices. However, strengthening the evidence
base that informs many key model assumptions and parameters remains imperative. Finally,
ceftriaxone (which is affected by the same resistance determinants as cefixime) is our last
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002423 October 31, 2017 3 / 5
remaining option for monotherapy of gonorrhea. Stronger multidisciplinary evidence and
widely implemented management guidelines are essential before we recommend the reintro-
duction of monotherapy with cefixime, which has previously, and might in the future, select
for resistance to ceftriaxone.
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